S

Stoke Therapeutics

D
STOK
USD
0.43
(3.0913%)
Market Open
16,642.00
Volume
-2.12
EPS
-
Div Yield
-6.525346
P/E
747,598,745.80
Market Cap
Today
1.7973%
1 Week
6.868%
1 Month
19.797%
6 Months
22.917%
12 Months
231.616%
Year To Date
168.691%
All Time
0%

Title:
Stoke Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
Do you need help or have a question?